2024

• Gunjur, A., Underhill, C., Frentzas, S., Michael, M., Gao, B., Palmer, J., Cebon, J., Behren, A., Adams, D., Lawley, T., Carlino, M., et al (2024). A gut microbial signature for combination immune checkpoint blockade across cancer types. Nature Medicine. [More Information]
• Gjorup, C., Woodford, R., Li, I., Carlino, M., Ch'ng, S., Chung, D., Hsiao, E., Lo, S., London, K., Long, G., Menzies, A., Nieweg, O., Pennington, T., Rtshiladze, M., Saw, R., Scolyer, R., Shannon, K., Spillane, A., Stretch, J., Thompson, J., Varey, A., van Akkooi, A. (2024). ASO Visual Abstract: Role of Concurrent Ultrasound Surveillance of Sentinel Node‑Positive Node Fields in Melanoma Patients Having Routine Cross‑Sectional Imaging. Annals of Surgical Oncology, 31(3), 1882-1883. [More Information]
• Wu, L., Tsang, V., Gunton, J., Carlino, M., Brown, D., Long, G., Clifton-Bligh, R., Mellor, R., Moore, K., Sasson, S., Menzies, A. (2024). Checkpoint Inhibitor-Associated Autoimmune Diabetes Mellitus Is Characterized by C-peptide Loss and Pancreatic Atrophy. Journal of Clinical Endocrinology and Metabolism, 109(5), 1301-1307. [More Information]
• McLean, L., Harris, S., Kukard, C., Zielinski, R., Alamgeer, M., Carlino, M., Mo, J., Park, J., Khattak, M., Day, F., et al (2024). Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study. Medical Journal of Australia, 220(2), 80-90. [More Information]
• Long, G., Blaustein, A., Lotem, M., Arance, A., Daud, A., Hamid, O., Larkin, J., Yao, L., Singh, R., Lal, R., Carlino, M., et al (2024). Pembrolizumab versus ipilimumab for advanced melanoma: 10-year follow-up of the phase III KEYNOTE-006 study. Annals of Oncology. [More Information]
• Luke, J., Kirkwood, J., Robert, C., Grob, J., De Galitiis, F., Schadendorf, D., Carlino, M., Wu, X., Fukunaga-Kalabis, M., Krepler, C., Long, G., et al (2024). Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study. Journal of Clinical Oncology, 42(14), 1619-1624. [More Information]
• Schadendorf, D., Luke, J., Ascierto, P., Long, G., Rutkowski, P., Khattak, A., Del Vecchio, M., de la Cruz Merino, L., MacKiewicz, J., Sileni, V., Carlino, M., Scolyer, R., et al (2024). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial. Journal for ImmunoTherapy of Cancer, 12(3). [More Information]
• Wang, X., Sun, J., Guo, J., Cui, C., Pan, H., Cui, J., Chen, X., Yoon, W., Carlino, M., Li, X., et al (2024). SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma. Immunotherapy, 16(4), 243-256. [More Information]
• Rogiers, A., Menzies, A., Long, G., Dimitriou, F., Lobon, I., Harvey, C., Vergara Correa, I., Esteves Domingues Pires da Silva, I., Lo, S., Scolyer, R., Carlino, M. (2024). Seasonal patterns of toxicity in melanoma patients treated with combination anti-PD-1 and anti-CTLA-4 immunotherapy. European Journal of Cancer, 198, 113506. [More Information]
• Bai, X., Attrill, G., Gide, T., Ferguson, P., Nahar, K., Shang, P., Vergara Correa, I., Palendira, M., Esteves Domingues Pires da Silva, I., Carlino, M., Menzies, A., Long, G., Scolyer, R., Wilmott, J., Quek, C. (2024). Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma. Nature Communications, 15(1), 3014. [More Information]

2023

• Piperno-Neumann, S., Carlino, M., Boni, V., Loirat, D., Speetjens, F., Park, J., Calvo, E., Carvajal, R., Nyakas, M., Gonzalez-Maffe, J., et al (2023). A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma. British Journal of Cancer, 128(6), 1040-1051. [More Information]
• Weber, J., Schadendorf, D., Del Vecchio, M., Larkin, J., Atkinson, V., Schenker, M., Pigozzo, J., Gogas, H., Dalle, S., Meyer, N., Carlino, M., Menzies, A., et al (2023). Adjuvant Therapy of Nivolumab Combined with Ipilimumab Versus Nivolumab Alone in Patients with Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915). Journal of Clinical Oncology, 41(3), 517-527. [More Information]
• Lee, J., Ahmed, T., Maurichi, A., Di Guardo, L., Stagno, A., Warburton, L., Taylor, A., Livingstone, E., Rehman, S., Khattak, A., Lo, S., Long, G., Menzies, A., Carlino, M., et al (2023). BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes. European Journal of Cancer, 179, 87-97. [More Information]
• Adegoke, N., Gide, T., Mao, Y., Quek, C., Patrick, E., Carlino, M., Lo, S., Menzies, A., Esteves Domingues Pires da Silva, I., Vergara Correa, I., Long, G., Scolyer, R., Wilmott, J. (2023). Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies. Journal for ImmunoTherapy of Cancer, 11(10). [More Information]
• Mao, Y., Gide, T., Adegoke, N., Quek, C., Maher, N., Potter, A., Patrick, E., Saw, R., Thompson, J., Spillane, A., Shannon, K., Carlino, M., Lo, S., Menzies, A., Da Silva, I., Long, G., Scolyer, R., Wilmott, J. (2023). Cross‑platform comparison of immune signatures in immunotherapy‑treated patients with advanced melanoma using a rank‑based scoring approach. Journal of Translational Medicine, 21(Green Open Access), Article 257-16 pages. [More Information]
• Weppler, A., Da Meda, L., Esteves Domingues Pires da Silva, I., Xu, W., Grignani, G., Menzies, A., Carlino, M., Long, G., Lo, S., Nordman, I., et al (2023). Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation. European Journal of Cancer, 183, 109-118. [More Information]
• Wong, S., Blum, S., Sun, X., Esteves Domingues Pires da Silva, I., Zubiri, L., Ye, F., Bai, K., Zhang, K., Ugurel, S., Zimmer, L., Long, G., Carlino, M., Menzies, A., et al (2023). Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma. European Journal of Cancer, 181, 188-197. [More Information]
• Bhave, P., Hong, A., Lo, S., Johnson, R., Mangana, J., Johnson, D., Dulgar, O., Eroglu, Z., Yeoh, H., Haydon, A., Menzies, A., Long, G., et al (2023). Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy. Journal for ImmunoTherapy of Cancer, 11(3). [More Information]
• Cass, S., Mason, R., Millward, M., Sandhu, S., Khoo, C., Warburton, L., Guerra, V., Haydon, A., Dearden, H., Menzies, A., Carlino, M., Long, G., et al (2023). Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia. Annals of Oncology, 34(9), 796-805. [More Information]
• Lai-Kwon, J., Jacques, S., Carlino, M., Benannoune, N., Robert, C., Allayous, C., Baroudjian, B., Lebbe, C., Zimmer, L., Eroglu, Z., Lo, S., Menzies, A., Long, G., et al (2023). Efficacy of ipilimumab 3 mg/kg following progression on low-dose ipilimumab in metastatic melanoma. European Journal of Cancer, 186. [More Information]
• Goodman, R., Lawless, A., Woodford, R., Fa'Ak, F., Tipirneni, A., Patrinely, J., Yeoh, H., Rapisuwon, S., Haydon, A., Osman, I., Carlino, M., Menzies, A., et al (2023). Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma. JAMA Network Open, 6(8), E2327145. [More Information]
• Brown, L., Esteves Domingues Pires da Silva, I., Moujaber, T., Gao, B., Hui, R., Gurney, H., Carlino, M., Nagrial, A. (2023). Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres. Cancer Medicine, 12(6), 6788-6801. [More Information]
• Vergara Correa, I., Aivazian, K., Carlino, M., Guminski, A., Maher, N., Shannon, K., Ch'ng, S., Saw, R., Long, G., Wilmott, J., Scolyer, R. (2023). Genomic Profiling of Metastatic Basal cell Carcinoma Reveals Candidate Drivers of Disease and Therapeutic Targets. Modern Pathology, 36(4), 100099. [More Information]
• Varey, A., Thompson, J., Howle, J., Lo, S., Ch'ng, S., Carlino, M. (2023). Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary? European Journal of Cancer, 186, 166-171. [More Information]
• Shek, D., Gloss, B., Lai, J., Zhang, H., Carlino, M., Mahajan, H., Nagrial, A., Gao, B., Read, S., Ahlenstiel, G. (2023). Identification and Characterisation of Infiltrating Immune Cells in Malignant Pleural Mesothelioma Using Spatial Transcriptomics. Methods and Protocols, 6(2). [More Information]
• Ming, Z., Lim, S., Stewart, A., Pedersen, B., Shklovskaya, E., Menzies, A., Carlino, M., Kefford, R., Lee, J., Scolyer, R., Long, G., Rizos, H. (2023). IFN-γ Signaling Sensitizes Melanoma Cells to BH3 Mimetics. Journal of Investigative Dermatology. [More Information]
• Truong, K., Chamberlin, C., Kim, J., Carlino, M., Ruiz Araujo, R. (2023). Immune checkpoint inhibitor-induced lichenoid drug eruption-sparing scar burns. Australasian Journal of Dermatology.
• Hasmat, S., Howle, J., Carlino, M., Sundaresan, P., Veness, M. (2023). Immunotherapy in advanced cutaneous squamous cell carcinoma: Sydney west cancer network experience. ANZ Journal of Surgery, 93(1-2), 235-241. [More Information]
• Lee, H., Ferguson, A., Quek, C., Vergara Correa, I., Esteves Domingues Pires da Silva, I., Allen, R., Gide, T., Conway, J., Koufariotis, L., Hayward, N., Carlino, M., Menzies, A., Saw, R., Shklovskaya, E., Rizos, H., Lo, S., Scolyer, R., Long, G., Palendira, M., Wilmott, J., et al (2023). Intratumoral CD16þ Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy. Clinical Cancer Research, 29(13), 2513-2524. [More Information]
• Truong, K., Jones-Caballero, M., Chou, S., Carlino, M., Consuegra-Romero, G., Ruiz Araujo, R. (2023). Lichen sclerosus and immune checkpoint inhibitors: A case and review of the literature. Australasian Journal of Dermatology, 64(1), 158-161. [More Information]
• Park, B., Narayanan, S., Gavraldis, A., Ye, F., Fan, R., Sullivan, R., Boland, G., Reynolds, K., Balko, J., Carlino, M., Long, G., Menzies, A., et al (2023). Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations. OncoImmunology, 12(1). [More Information]
• Wu, L., Tsang, V., Menzies, A., Sasson, S., Carlino, M., Brown, D., Clifton-Bligh, R., Gunton, J. (2023). Risk Factors and Characteristics of Checkpoint Inhibitor– Associated Autoimmune Diabetes Mellitus (CIADM): A Systematic Review and Delineation From Type 1 Diabetes. Diabetes Care, 46(6), 1292-1299. [More Information]
• Gjorup, C., Woodford, R., Li, I., Carlino, M., Ch'ng, S., Chung, D., Hsiao, E., Lo, S., London, K., Long, G., Menzies, A., Nieweg, O., Pennington, T., Rtshiladze, M., Saw, R., Scolyer, R., Shannon, K., Spillane, A., Stretch, J., Thompson, J., Varey, A., van Akkooi, A. (2023). Role of Concurrent Ultrasound Surveillance of Sentinel Node-Positive Node Fields in Melanoma Patients Having Routine Cross-Sectional Imaging. Annals of Surgical Oncology, 31(3), 1857-1864. [More Information]
• Lim, S., Shklovskaya, E., Lee, J., Pedersen, B., Stewart, A., Ming, Z., Irvine, M., Shivalingam, B., Saw, R., Menzies, A., Carlino, M., Scolyer, R., Long, G., Rizos, H. (2023). The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma. Nature Communications, 14(1). [More Information]
• Conway, J., Braden, J., Lo, S., Scolyer, R., Carlino, M., Menzies, A., Long, G., Esteves Domingues Pires da Silva, I. (2023). VEGF Inhibitors Improve Survival Outcomes in Patients with Liver Metastases across Cancer Types-A Meta-Analysis. Cancers, 15(20), 5012. [More Information]

2022

• Khattak, M., Luke, J., Long, G., Ascierto, P., Rutkowski, P., Schadendorf, D., Robert, C., Grob, J., de la Cruz Merino, L., Del Vecchio, M., Carlino, M., et al (2022). Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study. European Journal of Cancer, 176, 207-217. [More Information]
• Diefenbach, R., Lee, J., Stewart, A., Menzies, A., Carlino, M., Saw, R., Stretch, J., Long, G., Scolyer, R., Rizos, H. (2022). Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Frontiers in Oncology, 12, 820510. [More Information]
• Long, G., Arance, A., Mortier, L., Lorigan, P., Blank, C., Mohr, P., Schachter, J., Grob, J., Lotem, M., Middleton, M., Carlino, M., et al (2022). Antitumor activity of ipilimumab or BRAF ± MEK inhibition after pembrolizumab treatment in patients with advanced melanoma: analysis from KEYNOTE-006. Annals of Oncology, 33(2), 204-215. [More Information]
• Muir, C., Wood, C., Clifton-Bligh, R., Long, G., Scolyer, R., Carlino, M., Menzies, A., Tsang, V. (2022). Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events. Journal of Clinical Endocrinology and Metabolism, 107(5), e1843-e1849. [More Information]
• Scolyer, R., Atkinson, V., Gyorki, D., Lambie, D., O'Toole, S., Saw, R., Amanuel, B., Angel, C., Button-Sloan, A., Carlino, M., Ch'ng, S., Daneshvar, D., Esteves Domingues Pires da Silva, I., Ferguson, P., Gill, A., Gupta, R., Hong, A., Howle, J., Jackett, L., Lee, C., et al (2022). BRAF mutation testing for patients diagnosed with stage III or stage IV melanoma: practical guidance for the Australian setting. Pathology, 54(1), 6-19. [More Information]
• Esteves Domingues Pires da Silva, I., Ahmed, T., McQuade, J., Nebhan, C., Park, J., Versluis, J., Serra-Bellver, P., Khan, Y., Slattery, T., Oberoi, H., Utikal, J., Rai, R., Scolyer, R., Carlino, M., Hui, R., et al (2022). Clinical Models to Define Response and Survival With Anti-PD-1 Antibodies Alone or Combined With Ipilimumab in Metastatic Melanoma. Journal of Clinical Oncology, 40(10), 1068-1080. [More Information]
• Pennington, T., Zhao, C., Colebatch, A., Fernandez Penas, P., Guitera, P., Burke, H., Scolyer, R., Menzies, A., Carlino, M., Lo, S., Long, G., Saw, R. (2022). Clinicopathological characteristics of new primary melanomas in patients receiving immune checkpoint inhibitor therapy for metastatic melanoma. Australasian Journal of Dermatology, 63(2), e133-e137. [More Information]
• Nahar, K., Marsh-Wakefield, F., Rawson, R., Gide, T., Ferguson, A., Allen, R., Quek, C., Esteves Domingues Pires da Silva, I., Tattersal, S., Kiely, C., Carlino, M., McCaughan, G., Wilmott, J., Scolyer, R., Long, G., Menzies, A., Palendira, M., et al (2022). Distinct pretreatment innate immune landscape and posttreatment T cell responses underlie immunotherapy-induced colitis. JCI Insight, 7(21). [More Information]
• Hanna, S., Marinos, E., Bryan, D., Ahmed, T., Lo, S., Carlino, M., Smith, A., Cairns, G., Shannon, K., Long, G., Scolyer, R., Saw, R. (2022). Effect of the SunSafe Student Ambassador Program on the attitudes, knowledge and behaviour of Australian high-school students towards sun safety: a prospective study. Clinical and Experimental Dermatology, 47(11), 1956-1967. [More Information]
• Esteves Domingues Pires da Silva, I., Zakria, D., Ahmed, T., Trojanello, C., Dimitriou, F., Allayous, C., Gerard, C., Zimmer, L., Lo, S., Michielin, O., Carlino, M., Menzies, A., Long, G., et al (2022). Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma. Journal for ImmunoTherapy of Cancer, 10(7). [More Information]
• Dimitriou, F., Lo, S., Tan, A., Emmett, L., Kapoor, R., Carlino, M., Long, G., Menzies, A. (2022). FDG-PET to predict long-term outcome from anti-PD-1 therapy in metastatic melanoma. Annals of Oncology, 33(1), 99-106. [More Information]
• Attrill, G., Owen, C., Ahmed, T., Vergara Correa, I., Colebatch, A., Conway, J., Nahar, K., Thompson, J., Esteves Domingues Pires da Silva, I., Carlino, M., Menzies, A., Lo, S., Palendira, M., Scolyer, R., Long, G., Wilmott, J. (2022). Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy. Journal for ImmunoTherapy of Cancer, 10(6). [More Information]
• Maio, M., Carlino, M., Joshua, A., McWhirter, E., Ribas, A., Ascierto, P., Miller, W., Butler, M., Ferrucci, P., Zielinski, R., et al (2022). KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. European Journal of Cancer, 160, 1-11. [More Information]
• Wolchok, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Rutkowski, P., Lao, C., Cowey, C., Schadendorf, D., Wagstaff, J., Dummer, R., Carlino, M., Long, G., et al (2022). Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. Journal of Clinical Oncology, 40(2), 127-137. [More Information]
• Newell, F., Esteves Domingues Pires da Silva, I., Johansson, P., Menzies, A., Wilmott, J., Addala, V., Carlino, M., Rizos, H., Nones, K., Edwards, J., Ferguson, P., Thompson, J., Spillane, A., Saw, R., Shannon, K., Mann, G., Scolyer, R., Long, G., et al (2022). Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance. Cancer Cell, 40(1), 88-1.02E+09. [More Information]
• Dey, A., Manolios, N., Long, G., Carlino, M., Kefford, R., Schrieber, L. (2022). Musculoskeletal immune-related adverse events with the use of checkpoint inhibitors in malignancy. Internal Medicine Journal, 52(5), 818-827. [More Information]
• Smith, J., Menzies, A., Cohen, J., Mut-Lloret, M., Ozgun, A., Spain, L., Park, J., Quach, H., Pallan, L., McQuade, J., Long, G., Carlino, M., et al (2022). Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: A multicenter case series. Melanoma Research, 32(6), 451-459. [More Information]
• Luke, J., Rutkowski, P., Queirolo, P., Del Vecchio, M., Mackiewicz, J., Chiarion-Sileni, V., de la Cruz Merino, L., Khattak, M., Schadendorf, D., Long, G., Carlino, M., Scolyer, R., et al (2022). Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. The Lancet, 399(10336), 1718-1729. [More Information]
• Long, G., Luke, J., Khattak, M., de la Cruz Merino, L., Del Vecchio, M., Rutkowski, P., Spagnolo, F., Mackiewicz, J., Chiarion-Sileni, V., Kirkwood, J., Carlino, M., et al (2022). Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial. The Lancet Oncology, 23(11), 1378-1388. [More Information]
• Schuler, M., Zimmer, L., Kim, K., Sosman, J., Ascierto, P., Postow, M., de Vos, F., van Herpen, C., Carlino, M., Johnson, D., et al (2022). Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma. Clinical Cancer Research, 28(14), 3002-3010. [More Information]
• Eggermont, A., Ascierto, P., Khushalani, N., Schadendorf, D., Boland, G., Weber, J., Lewis, K., Johnson, D., Rivalland, G., Khattak, A., Long, G., Carlino, M., et al (2022). PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence. Future Oncology, 18(8), 903-913. [More Information]
• Kennedy, O., Kicinski, M., Valpione, S., Gandini, S., Suciu, S., Blank, C., Long, G., Atkinson, V., Dalle, S., Haydon, A., Carlino, M., et al (2022). Prognostic and predictive value of β-blockers in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma. European Journal of Cancer, 165, 97-112. [More Information]
• Park, J., Stewart, A., Irvine, M., Pedersen, B., Ming, Z., Carlino, M., Diefenbach, R., Rizos, H. (2022). Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling. Cancer Gene Therapy, 29(10), 1384-1393. [More Information]
• Serra-Bellver, P., Versluis, J., Oberoi, H., Zhou, C., Slattery, T., Khan, Y., Patrinely, J., Esteves Domingues Pires da Silva, I., Martínez-Vila, C., Cook, N., Carlino, M., Menzies, A., Long, G., et al (2022). Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study. European Journal of Cancer, 176, 121-132. [More Information]
• Dimitriou, F., Namikawa, K., Reijers, I., Buchbinder, E., Soon, J., Zaremba, A., Teterycz, P., Mooradian, M., Armstrong, E., Nakamura, Y., Carlino, M., et al (2022). Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study. Annals of Oncology, 33(9), 968-980. [More Information]
• Conway, J., Rawson, R., Lo, S., Ahmed, T., Vergara Correa, I., Gide, T., Attrill, G., Carlino, M., Saw, R., Thompson, J., Spillane, A., Shannon, K., Shivalingam, B., Menzies, A., Wilmott, J., Long, G., Scolyer, R., Esteves Domingues Pires da Silva, I. (2022). Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites. Journal for ImmunoTherapy of Cancer, 10(9). [More Information]

2021

• Randall Patrinely, J., Funck-Brentano, E., Nguyen, K., Rapisuwon, S., Salem, J., Gibney, G., Carlino, M., Johnson, D. (2021). A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis. The Oncologist, 26(3), e505-e507. [More Information]
• Livingstone (nee Ratcliffe), A., Dempsey, K., Stockler, M., Howard, K., Long, G., Carlino, M., Menzies, A., Morton, R. (2021). Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews. BMC Cancer, 21(1), 1014. [More Information]
• Bottomley, A., Coens, C., Mierzynska, J., Blank, C., Mandalà, M., Long, G., Atkinson, V., Dalle, S., Haydon, A., Meshcheryakov, A., Carlino, M., et al (2021). Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. The Lancet Oncology, 22(5), 655-664. [More Information]
• Li, A., Vakharia, K., Lo, S., Varey, A., Carlino, M., Saw, R., Shannon, K., Howle, J., Pennington, T., Stretch, J., Nieweg, O., Spillane, A., Long, G., Menzies, A., Scolyer, R., Thompson, J., Ch'ng, S. (2021). ASO Visual Abstract: Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma. Annals of Surgical Oncology, 28, 597-598. [More Information]
• Patrinely, J., Johnson, R., Lawless, A., Bhave, P., Sawyers, A., Dimitrova, M., Yeoh, H., Palmeri, M., Ye, F., Fan, R., Long, G., Menzies, A., et al (2021). Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma. JAMA Oncology, 7(5), 744-748. [More Information]
• Park, J., Diefenbach, R., Byrne, N., Long, G., Scolyer, R., Gray, E., Carlino, M., Rizos, H. (2021). Circulating tumor dna reflects uveal melanoma responses to protein kinase c inhibition. Cancers, 13(7), 1740-1-1740-14. [More Information]
• Gandini, S., Zanna, I., De Angelis, S., Cocorocchio, E., Queirolo, P., Lee, J., Carlino, M., Mazzarella, L., Achutti Duso, B., Palli, D., et al (2021). Circulating tumour DNA and melanoma survival: A systematic literature review and meta-analysis. Critical Reviews in Oncology / Hematology (online), 157, 103187. [More Information]
• Gide, T., Esteves Domingues Pires da Silva, I., Quek, C., Ferguson, P., Batten, M., Shang, P., Ahmed, T., Menzies, A., Carlino, M., Saw, R., Thompson, J., Scolyer, R., Long, G., Wilmott, J. (2021). Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. Cancers, 13(13), 3186-1-3186-16. [More Information]
• Rogiers, A., Da Silva, I., Tentori, C., Tondini, C., Grimes, J., Trager, M., Nahm, S., Zubiri, L., Manos, M., Bowling, P., Menzies, A., Carlino, M., et al (2021). Clinical impact of COVID-19 on patients with cancer treated with immune checkpoint inhibition. Journal for ImmunoTherapy of Cancer, 9(1), e001931. [More Information]
• Brown, L., Weppler, A., Bhave, P., Allayous, C., Patrinely, J., Ott, P., Sandhu, S., Haydon, A., Lebbé, C., Johnson, D., Long, G., Menzies, A., Carlino, M. (2021). Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. Journal for ImmunoTherapy of Cancer, 9(5), e002121. [More Information]
• Klein, O., Senko, C., Carlino, M., Markman, B., Jackett, L., Gao, B., Kee, D., Behren, A., Palmer, J., Cebon, J. (2021). Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538. OncoImmunology, 10(1), 1908771. [More Information]
• Klein, O., Kee, D., Gao, B., Markman, B., Da Gama Duarte, J., Quigley, L., Jackett, L., Linklater, R., Strickland, A., Scott, C., Carlino, M., et al (2021). Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial. Journal for ImmunoTherapy of Cancer, 9(11), e003156. [More Information]
• Klein, O., Kee, D., Markman, B., Carlino, M., Underhill, C., Palmer, J., Power, D., Cebon, J., Behren, A. (2021). Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy. Cancer Cell, 39(5), 592-593. [More Information]
• Zaremba, A., Kramer, R., De Temple, V., Bertram, S., Salzmann, M., Gesierich, A., Reinhardt, L., Baroudjian, B., Sachse, M., Mechtersheimer, G., Long, G., Menzies, A., Carlino, M., et al (2021). Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis. Frontiers in Oncology, 11, 765608. [More Information]
• Dearden, H., Au, L., Wang, D., Zimmer, L., Eroglu, Z., Smith, J., Cuvietto, M., Khoo, C., Atkinson, V., Lo, S., Long, G., Carlino, M., Menzies, A., et al (2021). Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer, 153, 168-178. [More Information]
• Carlino, M., Larkin, J., Long, G. (2021). Immune checkpoint inhibitors in melanoma. The Lancet, 398(10304), 1002-1014. [More Information]
• Shek, D., Read, S., Nagrial, A., Carlino, M., Gao, B., George, J., Ahlenstiel, G. (2021). Immune-Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Synopsis of Response Rates. The Oncologist, 26(7), e1216-e1225. [More Information]
• Shek, D., Akhuba, L., Carlino, M., Nagrial, A., Moujaber, T., Read, S., Gao, B., Ahlenstiel, G. (2021). Immune-checkpoint inhibitors for metastatic colorectal cancer: A systematic review of clinical outcomes. Cancers, 13(17), 4345. [More Information]
• Hasmat, S., Howle, J., Karikios, D., Carlino, M., Veness, M. (2021). Immunotherapy in advanced Merkel cell carcinoma: Sydney west cancer network experience. Journal of Medical Imaging and Radiation Oncology, 65(6), 760-767. [More Information]
• Esteves Domingues Pires da Silva, I., Ahmed, T., Reijers, I., Weppler, A., Betof Warner, A., Patrinely, J., Serra-Bellver, P., Allayous, C., Mangana, J., Nguyen, K., Carlino, M., Lo, S., Menzies, A., Long, G., et al (2021). Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study. The Lancet Oncology, 22(6), 836-847. [More Information]
• Da Silva, I., Ahmed, T., Reijers, I., Warner, A., Patrinely, J., Serra-Bellver, P., Allayous, C., Mangana, J., Zimmer, L., Trojaniello, C., Carlino, M., Lo, S., Menzies, A., Long, G., et al (2021). Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma – Authors' reply. The Lancet Oncology, 22(8), e343-e344. [More Information]
• Hamid, O., Robert, C., Daud, A., Carlino, M., Mitchell, T., Hersey, P., Schachter, J., Long, G., Hodi, F., Wolchok, J., Joshua, A., et al (2021). Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006. European Journal of Cancer, 157, 391-402. [More Information]
• Robert, C., Hwu, W., Hamid, O., Ribas, A., Weber, J., Daud, A., Hodi, F., Wolchok, J., Mitchell, T., Hersey, P., Long, G., Carlino, M., Joshua, A., et al (2021). Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanoma. European Journal of Cancer, 144, 182-191. [More Information]
• Hong, A., Waldstein, C., Shivalingam, B., Carlino, M., Atkinson, V., Kefford, R., McArthur, G., Menzies, A., Thompson, J., Long, G. (2021). Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia. European Journal of Cancer, 142, 10-17. [More Information]
• Waldstein, C., Wang, T., Lo, S., Shivalingam, B., Fogarty, G., Carlino, M., Menzies, A., Long, G., Hong, A. (2021). Melanoma brain metastases: The outcome of whole brain radiation therapy in the era of effective systemic therapy. Therapeutic Radiology and Oncology, 5(3), 11. [More Information]
• Howle, J., Varey, A., Carlino, M. (2021). Melanoma management in the 21st century: a change in paradigm. ANZ Journal of Surgery, 91(12), 2557-2558. [More Information]
• Bhave, P., Pallan, L., Long, G., Menzies, A., Atkinson, V., Cohen, J., Sullivan, R., Chiarion-Sileni, V., Nyakas, M., Kahler, K., Carlino, M., et al (2021). Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. British Journal of Cancer, 124(3), 574-580. [More Information]
• Parakh, S., Musafer, A., Paessler, S., Witkowski, T., Suen, C., Tutuka, C., Carlino, M., Menzies, A., Scolyer, R., Cebon, J., Long, G., et al (2021). PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma. Frontiers in Immunology, 12. [More Information]
• Wang, T., Smith, J., Carlino, M., Burmeister, B., Pinkham, M., Fogarty, G., Christie, D., Estall, V., Shackleton, M., Clements, A., et al (2021). Phase I/II trial of concurrent extracranial palliative radiation therapy with Dabrafenib and Trametinib in metastatic BRAF V600E/K mutation-positive cutaneous Melanoma. Clinical and Translational Radiation Oncology, 30, 95-99. [More Information]
• Ch'ng, S., Uyulmaz, S., Carlino, M., Pennington, T., Shannon, K., Rtshiladze, M., Stretch, J., Nieweg, O., Varey, A., Hsiao, E., Kapoor, R., Esteves Domingues Pires da Silva, I., Lo, S., Spillane, A., Scolyer, R., Long, G., Hong, A., Saw, R., Thompson, J., Menzies, A. (2021). Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies. European Journal of Cancer, 153, 8-15. [More Information]
• Hepner, A., Atkinson, V., Larkin, J., Burrell, R., Carlino, M., Johnson, D., Zimmer, L., Tsai, K., Klein, O., Lo, S., Pallan, L., Esteves Domingues Pires da Silva, I., Long, G., Menzies, A., et al (2021). Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti–PD-1 therapy. European Journal of Cancer, 153, 213-222. [More Information]
• Eggermont, A., Blank, C., Mandala, M., Long, G., Atkinson, V., Dalle, S., Haydon, A., Meshcheryakov, A., Khattak, A., Carlino, M., Sandhu, S., Larkin, J., Puig, S., Ascierto, P., Rutkowski, P., Schadendorf, D., Koornstra, R., Hernandez-Aya, L., Di Giacomo, A., van den Eertwegh, A., Grob, J., Gutzmer, R., Jamal, R., Lorigan, P., van Akkooi, A., Krepler, C., Ibrahim, N., Marreaud, S., Kicinski, M., Suciu, S. (2021). Reply to E. Hindié. Journal of Clinical Oncology, 39(8), 944-946. [More Information]
• Choi, S., Hong, A., Wang, T., Lo, S., Chen, B., Silva, I., Kapoor, R., Hsiao, E., Fogarty, G., Carlino, M., Menzies, A., Long, G., et al (2021). Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location. Strahlentherapie und Onkologie, 197(12), 1104-1112. [More Information]
• Long, G., Robert, C., Butler, M., Couture, F., Carlino, M., O’Day, S., Atkinson, V., Cebon, J., Brown, M., Dalle, S., Menzies, A., et al (2021). Standard-dose pembrolizumab plus alternate-dose ipilimumab in advanced melanoma: KEYNOTE-029 cohort 1C, a phase 2 randomized study of two dosing schedules. Clinical Cancer Research, 27(19), 5280-5288. [More Information]
• Li, A., Vakharia, K., Lo, S., Varey, A., Carlino, M., Saw, R., Shannon, K., Howle, J., Pennington, T., Stretch, J., Nieweg, O., Spillane, A., Long, G., Menzies, A., Scolyer, R., Thompson, J., Ch'ng, S. (2021). Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma. Annals of Surgical Oncology, 28(11), 6109-6123. [More Information]
• Versluis, J., Hendriks, A., Weppler, A., Brown, L., de Joode, K., Suijkerbuijk, K., Zimmer, L., Kapiteijn, E., Allayous, C., Johnson, D., Menzies, A., Long, G., Carlino, M., et al (2021). The role of local therapy in the treatment of solitary melanoma progression on immune checkpoint inhibition: A multicentre retrospective analysis. European Journal of Cancer, 151, 72-83. [More Information]
• Muir, C., Clifton-Bligh, R., Long, G., Scolyer, R., Lo, S., Carlino, M., Tsang, V., Menzies, A. (2021). Thyroid Immune-related Adverse Events following Immune Checkpoint Inhibitor Treatment. Journal of Clinical Endocrinology and Metabolism, 106(9), E3704-E3713. [More Information]
• Wu, L., Tsang, V., Sasson, S., Menzies, A., Carlino, M., Brown, D., Clifton-Bligh, R., Gunton, J. (2021). Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside. Frontiers in Endocrinology, 12, 764138. [More Information]

2020

• Sullivan, R., Weber, J., Patel, S., Dummer, R., Carlino, M., Tan, D., Lebbé, C., Siena, S., Elez, E., Wollenberg, L., et al (2020). A Phase Ib/II Study of the BRAF Inhibitor Encorafenib plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K-mutant Solid Tumors. Clinical Cancer Research, 26(19), 5102-5112. [More Information]
• Eggermont, A., Kicinski, M., Blank, C., Mandalà, M., Long, G., Atkinson, V., Dalle, S., Haydon, A., Khattak, A., Carlino, M., et al (2020). Association between Immune-Related Adverse Events and Recurrence-Free Survival among Patients with Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncology, 6(4), 519-527. [More Information]
• Puzanov, I., Ribas, A., Robert, C., Schachter, J., Nyakas, M., Daud, A., Arance, A., Carlino, M., O'Day, S., Long, G., et al (2020). Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition with Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials. JAMA Oncology, 6(8), 1256-1264. [More Information]
• Marsavela, G., Lee, J., Calapre, L., Wong, S., Pereira, M., McEvoy, A., Reid, A., Robinson, C., Warburton, L., Abed, A., Carlino, M., Menzies, A., Scolyer, R., Long, G., Rizos, H., et al (2020). Circulating Tumor DNA Predicts Outcome from First-, but not Second-line Treatment and Identifies Melanoma Patients Who May Benefit from Combination Immunotherapy. Clinical Cancer Research, 26(22), 5926-5933. [More Information]
• Nahar, K., Rawson, R., Ahmed, T., Tattersall, S., Sandanayake, N., Kiely, C., Lo, S., Carlino, M., Palendira, M., Scolyer, R., Long, G., Menzies, A. (2020). Clinicopathological characteristics and management of colitis with anti-PD1 immunotherapy alone or in combination with ipilimumab. Journal for ImmunoTherapy of Cancer, 8(2), 1-12. [More Information]
• Gide, T., Da Silva, I., Quek, C., Ahmed, T., Menzies, A., Carlino, M., Saw, R., Thompson, J., Batten, M., Long, G., Scolyer, R., Wilmott, J. (2020). Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients. OncoImmunology, 9(1), 1659093. [More Information]
• Mason, R., Dearden, H., Nguyen, B., Soon, J., Smith, J., Randhawa, M., Mant, A., Warburton, L., Lo, S., Meniawy, T., Guminski, A., Long, G., Carlino, M., Menzies, A., et al (2020). Combined ipilimumab and nivolumab first-line and after BRAF targeted therapy in advanced melanoma. Pigment Cell & Melanoma Research, 33(2), 358-365. [More Information]
• Haydu, L., Lo, S., McQuade, J., Amaria, R., Wargo, J., Ross, M., Cormier, J., Lucci, A., Lee, J., Ferguson, S., Saw, R., Spillane, A., Shannon, K., Stretch, J., Carlino, M., Menzies, A., Long, G., Scolyer, R., Thompson, J., et al (2020). Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. Journal of Clinical Oncology, 38(13), 1429-1441. [More Information]
• Diefenbach, R., Lee, J., Menzies, A., Carlino, M., Long, G., Saw, R., Howle, J., Spillane, A., Scolyer, R., Kefford, R., Rizos, H. (2020). Design and Testing of a Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA. Cancers, 12(8), 1-16. [More Information]
• Clark, M., Rizos, H., Pereira, M., McEvoy, A., Marsavela, G., Calapre, L., Meehan, K., Ruhen, O., Khattak, M., Meniawy, T., Long, G., Carlino, M., Menzies, A., et al (2020). Detection of BRAF splicing variants in plasma-derived cell-free nucleic acids and extracellular vesicles of melanoma patients failing targeted therapy therapies. Oncotarget, 11(44), 4016-4027. [More Information]
• Lee, J., Carlino, M., Rizos, H. (2020). Dosing of BRAK and MEK Inhibitors in Melanoma: No Point in Taking a Break. Cancer Cell, 38(6), 779-781. [More Information]
• Klein, O., Kee, D., Nagrial, A., Markman, B., Underhill, C., Michael, M., Jackett, L., Lum, C., Behren, A., Palmer, J., Carlino, M., et al (2020). Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients with Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial. JAMA Oncology, 6(9), 1405-1409. [More Information]
• Klein, O., Kee, D., Markman, B., Michael, M., Underhill, C., Carlino, M., Jackett, L., Lum, C., Scott, C., Nagrial, A., et al (2020). Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: A subgroup analysis of the CA209-538 clinical trial for rare cancers. Clinical Cancer Research, 26(17), 4454-4459. [More Information]
• Carlino, M., Menzies, A., Atkinson, V., Cebon, J., Jameson, M., Fitzharris, B., McNeil, C., Hill, A., Ribas, A., Atkins, M., Guminski, A., Kefford, R., Long, G., et al (2020). Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Clinical Cancer Research, 26(19), 5086-5091. [More Information]
• Eggermont, A., Blank, C., Mandala, M., Long, G., Atkinson, V., Dalle, S., Haydon, A., Meshcheryakov, A., Khattak, A., Carlino, M., et al (2020). Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: Updated results from the EORTC 1325-MG/KEYNOTE-054 trial. Journal of Clinical Oncology, 38(33), 3925-3936. [More Information]
• Lee, J., Menzies, A., Carlino, M., McEvoy, A., Sandhu, S., Weppler, A., Diefenbach, R., Dawson, S., Kefford, R., Millward, M., Scolyer, R., Long, G., Rizos, H., et al (2020). Longitudinal Monitoring of ctDNA in Patients with Melanoma and Brain Metastases Treated with Immune Checkpoint Inhibitors. Clinical Cancer Research, 26(15), 4064-4071. [More Information]
• Owen, C., Shoushtari, A., Chauhan, D., Palmieri, D., Lee, B., Rohaan, M., Mangana, J., Atkinson, V., Zaman, F., Young, A., Hersey, P., Lo, S., Carlino, M., Menzies, A., Long, G., et al (2020). Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. Annals of Oncology, 31(8), 1075-1082. [More Information]
• Sasson, S., Zaunders, J., Nahar, K., Munier, C., Fairfax, B., Olsson-Brown, A., Jolly, C., Read, S., Ahlenstiel, G., Palendira, M., Carlino, M., Long, G., Menzies, A., et al (2020). Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis. Clinical and Experimental Immunology, 202(3), 335-352. [More Information]
• Shek, D., Read, S., Akhuba, L., Qiao, L., Gao, B., Nagrial, A., Carlino, M., Ahlenstiel, G. (2020). Non-coding RNA and immune-checkpoint inhibitors: Friends or foes? Immunotherapy, 12(7), 513-529. [More Information]
• Pirozyan, M., McGuire, H., Emran, A., Tseng, H., Tiffen, J., Lee, J., Carlino, M., Menzies, A., Long, G., Scolyer, R., Fazekas de St Groth, B., Hersey, P. (2020). Pretreatment Innate Cell Populations and CD4 T Cells in Blood Are Associated With Response to Immune Checkpoint Blockade in Melanoma Patients. Frontiers in Immunology, 11, 372. [More Information]
• Esteves Domingues Pires da Silva, I., Lo, S., Quek, C., Gonzalez, M., Carlino, M., Long, G., Menzies, A. (2020). Site-specific response patterns, pseudoprogression, and acquired resistance in patients with melanoma treated with ipilimumab combined with anti-PD-1 therapy. Cancer, 126(1), 86-97. [More Information]
• Chan, L., Hwang, S., Byth Wilson, K., Kyaw, M., Carlino, M., Chou, S., Fernandez Penas, P. (2020). Survival and prognosis of individuals receiving programmed cell death 1 inhibitor with and without immunologic cutaneous adverse events. Journal Of The American Academy Of Dermatology, 82(2), 311-316. [More Information]
• Wang, D., McQuade, J., Rai, R., Park, J., Zhao, S., Ye, F., Beckermann, K., Rubinstein, S., Johnpulle, R., Long, G., Carlino, M., Menzies, A., et al (2020). The Impact of Nonsteroidal Anti-Inflammatory Drugs, Beta Blockers, and Metformin on the Efficacy of Anti-PD-1 Therapy in Advanced Melanoma. The Oncologist, 25(3), e602-e605. [More Information]
• Lee, J., Shklovskaya, E., Lim, S., Carlino, M., Menzies, A., Stewart, A., Pedersen, B., Irvine, M., Alavi, S., Yang, J., Strbenac, D., Saw, R., Thompson, J., Wilmott, J., Scolyer, R., Long, G., et al (2020). Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition. Nature Communications, 11(1), 1-12. [More Information]
• Shklovskaya, E., Lee, J., Lim, S., Stewart, A., Pedersen, B., Ferguson, P., Saw, R., Thompson, J., Shivalingam, B., Carlino, M., Scolyer, R., Menzies, A., Long, G., Kefford, R., Rizos, H. (2020). Tumor mhc expression guides first-line immunotherapy selection in melanoma. Cancers, 12(11), 1-13. [More Information]
• Johansson, P., Brooks, K., Newell, F., Palmer, J., Wilmott, J., Pritchard, A., Broit, N., Wood, S., Carlino, M., Leonard, C., Rizos, H., Long, G., Mann, G., Scolyer, R., et al (2020). Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours. Nature Communications, 11(1), 1-8. [More Information]

2019

• Diefenbach, R., Lee, J., Strbenac, D., Yang, J., Menzies, A., Carlino, M., Long, G., Spillane, A., Stretch, J., Saw, R., Thompson, J., Ch'ng, S., Scolyer, R., Kefford, R., Rizos, H. (2019). Analysis of the whole-exome sequencing of tumor and circulating tumor DNA in metastatic melanoma. Cancers, 11(12), 1-14. [More Information]
• Lim, S., Lee, J., Gide, T., Menzies, A., Guminski, A., Carlino, M., Breen, E., Yang, J., Ghazanfar, S., Kefford, R., Scolyer, R., Long, G., Rizos, H. (2019). Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1–Based Immunotherapy. Clinical Cancer Research, 25(5), 1557-1563. [More Information]
• Ribas, A., Lawrence, D., Atkinson, V., Agarwal, S., Miller Jr, W., Carlino, M., Fisher, R., Long, G., Hodi, F., Tsoi, J., et al (2019). Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma. Nature Medicine, 25(6), 936?940. [More Information]
• Gide, T., Quek, C., Menzies, A., Tasker, A., Shang, P., Holst, J., Madore, J., Lim, S., Wongchenko, M., Lo, S., Carlino, M., Guminski, A., Saw, R., Pang, A., McGuire, H., Palendira, M., Thompson, J., Rizos, H., Da Silva, I., Batten, M., Scolyer, R., Long, G., Wilmott, J., et al (2019). Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy. Cancer Cell, 35(2), 238-255.e6. [More Information]
• Da Silva, I., Wang, K., Wilmott, J., Holst, J., Carlino, M., Park, J., Quek, C., Wongchenko, M., Yan, Y., Mann, G., Rai, R., Kefford, R., Rizos, H., Scolyer, R., Yang, J., Long, G., Menzies, A., et al (2019). Distinct molecular profiles and immunotherapy treatment outcomes of V600E and V600K BRAF-mutant melanoma. Clinical Cancer Research, 25(4), 1272-1279. [More Information]
• Long, G., Dummer, R., Hamid, O., Gajewski, T., Caglevic, C., Dalle, S., Arance, A., Carlino, M., Grob, J., Kim, T., et al (2019). Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. The Lancet Oncology, 20(8), 1083-1097. [More Information]
• Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Rutkowski, P., Lao, C., Cowey, C., Schadendorf, D., Wagstaff, J., Dummer, R., Carlino, M., Long, G., et al (2019). Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 381(16), 1535-1546. [More Information]
• Diefenbach, R., Lee, J., Chandler, D., Wang, Y., Pflueger, C., Long, G., Scolyer, R., Carlino, M., Menzies, A., Kefford, R., Rizos, H. (2019). Hypermethylation of circulating free DNA in cutaneous melanoma. Applied Sciences, 9(23), 1-17. [More Information]
• Da Silva, I., Glitza, I., Haydu, L., Johnpulle, R., Banks, P., Grass, G., Goldinger, S., Smith, J., Everett, A., Koelblinger, P., Guminski, A., Kapoor, R., Carlino, M., Wang, T., Lo, S., Hong, A., Long, G., Menzies, A., et al (2019). Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodies. Pigment Cell & Melanoma Research, 32(4), 553-563. [More Information]
• Lee, H., Quek, C., Da Silva, I., Tasker, A., Batten, M., Rizos, H., Lim, S., Gide, T., Shang, P., Attrill, G., Madore, J., Edwards, J., Carlino, M., Guminski, A., Saw, R., Thompson, J., Ferguson, P., Palendira, M., Menzies, A., Long, G., Scolyer, R., Wilmott, J. (2019). Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients. OncoImmunology, 8(2), e1537581-1-e1537581-10. [More Information]
• Luke, J., Ascierto, P., Carlino, M., Gershenwald, J., Grob, J., Hauschild, A., Kirkwood, J., Long, G., Mohr, P., Robert, C., Scolyer, R., et al (2019). KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncology, 16(3), 4429-4438. [More Information]
• Robert, C., Ribas, A., Schachter, J., Arance, A., Grob, J., Mortier, L., Daud, A., Carlino, M., McNeil, C., Lotem, M., Long, G., et al (2019). Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. The Lancet Oncology, 20(9), 1239-1251. [More Information]
• Lee, J., Saw, R., Thompson, J., Lo, S., Spillane, A., Shannon, K., Stretch, J., Howle, J., Menzies, A., Carlino, M., Long, G., Scolyer, R., et al (2019). Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients. Annals of Oncology, 30(5), 815-822. [More Information]
• Eggermont, A., Blank, C., Mandala, M., Long, G., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Carlino, M., et al (2019). Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. European Journal of Cancer, 116, 148-157. [More Information]
• Menzer, C., Menzies, A., Carlino, M., Reijers, I., Groen, E., Eigentler, T., De Groot, J., Van Der Veldt, A., Johnson, D., Meiss, F., Long, G., Kefford, R., et al (2019). Targeted Therapy in Advanced Melanoma With Rare BRAF Mutations. Journal of Clinical Oncology, 37(33), 3142-3151. [More Information]

2018

• Eggermont, A., Blank, C., Mandala, M., Long, G., Atkinson, V., Dalle, S., Haydon, A., Lichinitser, M., Khattak, A., Khattak, M., Carlino, M., et al (2018). Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. New England Journal of Medicine, 378(19), 1789-1801. [More Information]
• Kugel III, C., Douglass, S., Webster, M., Kaur, A., Liu, Q., Yin, X., Weiss, S., Darvishian, F., Al-Rohil, R., Ndoye, A., Rai, R., Carlino, M., Long, G., Menzies, A., et al (2018). Age Correlates with Response to Anti-PD1, Reflecting Age-Related Differences in Intratumoral Effector and Regulatory T-Cell Populations. Clinical Cancer Research, 24(21), 5347-5356. [More Information]
• Lee, J., Long, G., Menzies, A., Lo, S., Guminski, A., Whitbourne, K., Peranec, M., Scolyer, R., Kefford, R., Rizos, H., Carlino, M. (2018). Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti-Programmed Cell Death 1 Antibodies. JAMA Oncology, 4(5), 717-721. [More Information]
• McQuade, J., Daniel, C., Hess, K., Mak, C., Wang, D., Rai, R., Park, J., Haydu, L., Spencer, C., Wongchenko, M., Carlino, M., Long, G., Menzies, A., et al (2018). Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. The Lancet Oncology, 19(3), 310-322. [More Information]
• Valpione, S., Carlino, M., Mangana, J., Mooradian, M., McArthur, G., Schadendorf, D., Hauschild, A., Menzies, A., Arance, A., Ascierto, P., Park, J., Long, G., et al (2018). Corrigendum to Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*" [Eur J Cancer 91 (2018) 116-124]". European Journal of Cancer, 93, 158. [More Information]
• Wang, D., Salem, J., Cohen, J., Chandra, S., Menzer, C., Ye, F., Zhao, S., Das, S., Beckermann, K., Ha, L., Long, G., Carlino, M., Menzies, A., et al (2018). Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors A Systematic Review and Meta-analysis. JAMA Oncology, 4(12), 1721-1728. [More Information]
• Tan, A., Emmett, L., Lo, S., Liu, V., Kapoor, R., Carlino, M., Guminski, A., Long, G., Menzies, A. (2018). FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. Annals of Oncology, 29(10), 2115-2120. [More Information]
• Eroglu, Z., Zaretsky, J., Hu-Lieskovan, S., Kim, D., Algazi, A., Johnson, D., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., Carlino, M., Scolyer, R., Long, G., et al (2018). High response rate to PD-1 blockade in desmoplastic melanomas. Nature, 553(7688), 347-350. [More Information]
• Palmieri, D., Carlino, M. (2018). Immune Checkpoint Inhibitor Toxicity. Current Oncology Reports, 20(9), 1-12. [More Information]
• Zhao, C., Hwang, S., Anforth, R., Carlos, G., Chou, S., Carlino, M., Fernandez Penas, P. (2018). Incidence of Basal Cell Carcinoma and Squamous Cell Carcinoma in Patients on Antiprogrammed Cell Death-1 Therapy for Metastatic Melanoma. Journal of Immunotherapy, 41(7), 343-349. [More Information]
• Lee, J., Lyle, M., Menzies, A., Chan, M., Lo, S., Clements, A., Carlino, M., Kefford, R., Long, G. (2018). Metastasis-specific patterns of response and progression with anti-PD-1 treatment in metastatic melanoma. Pigment Cell & Melanoma Research, 31(3), 404-410. [More Information]
• Baird-Gunning, J., Weerasinghe, D., Silsby, M., Gawarikar, Y., Carlino, M., Smith, J., Vucic, S. (2018). Miller Fisher Syndrome Associated With Immunotherapy for Metastatic Melanoma. The Neurohospitalist, 8(4), 191-193. [More Information]
• Park, J., Diefenbach, R., Joshua, A., Kefford, R., Carlino, M., Rizos, H. (2018). Oncogenic signaling in uveal melanoma. Pigment Cell & Melanoma Research, 31(6), 661-672. [More Information]
• Carlino, M., Long, G., Schadendorf, D., Robert, C., Ribas, A., Richtig, E., Nyakas, M., Caglevic, C., Tarhini, A., Blank, C., et al (2018). Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial. European Journal of Cancer, 101(September 2018), 236-243. [More Information]
• Valpione, S., Carlino, M., Mangana, J., Mooradian, M., McArthur, G., Schadendorf, D., Hauschild, A., Menzies, A., Arance, A., Ascierto, P., Park, J., Rai, R., Long, G., et al (2018). Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. European Journal of Cancer, 91, 116-124. [More Information]
• Tio, M., Wang, X., Carlino, M., Shivalingam, B., Fogarty, G., Guminski, A., Lo, S., Hong, A., Menzies, A., Long, G. (2018). Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy. Pigment Cell & Melanoma Research, 31(4), 509-515. [More Information]

2017

• Hwang, S., Wakade, D., Kong, B., Carlino, M., Chou, S., Fernandez Penas, P. (2017). Acute Truncal Lymphedema Secondary to Axillary Metastatic Melanoma Presenting Like Cellulitis. Case Reports in Medicine, 2017, 1-3. [More Information]
• Menzies, A., Johnson, D., Ramanujam, S., Atkinson, V., Wong, A., Park, J., McQuade, J., Shoushtari, A., Tsai, K., Eroglu, Z., Guminski, A., Carlino, M., Long, G., et al (2017). Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Annals of Oncology, 28(2), 368-376. [More Information]
• Lee, J., Long, G., Boyd, S., Lo, S., Menzies, A., Tembe, V., Guminski, A., Jakrot, V., Scolyer, R., Mann, G., Kefford, R., Carlino, M., Rizos, H. (2017). Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma. Annals of Oncology, 28(5), 1130-1136. [More Information]
• Pupo, G., Boyd, S., Fung, C., Carlino, M., Menzies, A., Pedersen, B., Johansson, P., Hayward, N., Kefford, R., Scolyer, R., Long, G., Rizos, H. (2017). Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing. Biomarker Research, 5(17), 1-4. [More Information]
• Vilain, R., Menzies, A., Wilmott, J., Kakavand, H., Madore, J., Guminski, A., Liniker, E., Kong, B., Cooper, A., Howle, J., Saw, R., Jakrot, V., Lo, S., Thompson, J., Carlino, M., Kefford, R., Long, G., Scolyer, R. (2017). Dynamic changes in PD-L1 expression and immune infiltrates early during treatment predict response to PD-1 blockade in Melanoma. Clinical Cancer Research, 23(17), 5024-5033. [More Information]
• Parakh, S., Park, J., Mendis, S., Rai, R., Xu, W., Lo, S., Drummond, M., Rowe, C., Wong, A., McArthur, G., Guminski, A., Kefford, R., Long, G., Menzies, A., Carlino, M., et al (2017). Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. British Journal of Cancer, 116(12), 1558-1563. [More Information]
• Lim, S., Lee, J., Welsh, S., Ahn, S., Breen, E., Khan, A., Carlino, M., Menzies, A., Kefford, R., Scolyer, R., Long, G., et al (2017). Evaluation of two high-throughput proteomic technologies for plasma biomarker discovery in immunotherapy-treated melanoma patients. Biomarker Research, 5, 1-12. [More Information]
• Kakavand, H., Jackett, L., Menzies, A., Gide, T., Carlino, M., Saw, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R. (2017). Negative immune checkpoint regulation by VISTA: A mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients. Modern Pathology, 30(12), 1666-1676. [More Information]
• Wolchok, J., Chiarion-Sileni, V., Gonzalez, R., Rutkowski, P., Grob, J., Cowey, C., Lao, C., Wagstaff, J., Schadendorf, D., Carlino, M., Long, G., et al (2017). Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. New England Journal of Medicine, 377(14), 1345-1356. [More Information]
• Kakavand, H., Rawson, R., Pupo, G., Yang, J., Menzies, A., Carlino, M., Kefford, R., Howle, J., Saw, R., Thompson, J., Wilmott, J., Long, G., Scolyer, R., et al (2017). PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. Clinical Cancer Research, 23(20), 6054-6061. [More Information]
• Schachter, J., Ribas, A., Long, G., Arance, A., Grob, J., Mortier, L., Daud, A., Carlino, M., McNeil, C., Lotem, M., et al (2017). Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). The Lancet, 390(10105), 1853-1862. [More Information]
• Park, J., Boddy, A., Liu, X., Harris, D., Lee, V., Kefford, R., Carlino, M. (2017). Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis. Pigment Cell & Melanoma Research, 30(1), 68-71. [More Information]
• Delord, J., Robert, C., Nyakas, M., McArthur, G., Kudchakar, R., Mahipal, A., Yamada, Y., Sullivan, R., Arance, A., Kefford, R., Carlino, M., et al (2017). Phase I dose-escalation and -expansion study of the BRAF inhibitor encorafenib (LGX818) in metastatic BRAF-mutant melanoma. Clinical Cancer Research, 23(18), 5339-5348. [More Information]
• Naidoo, J., Wang, X., Woo, K., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J., Segal, N., Callahan, M., Lesokhin, A., Menzies, A., Carlino, M., Kong, B., Long, G., et al (2017). Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. Journal of Clinical Oncology, 35(7), 709-717. [More Information]
• Sidhu, P., Menzies, A., Long, G., Carlino, M., Lorens, S., Kapoor, R. (2017). Radiological manifestations of immune-related adverse effects observed in patients with melanoma undergoing immunotherapy. Journal of Medical Imaging and Radiation Oncology, 61(6), 759-766. [More Information]
• Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., Guminski, A., Long, G., Carlino, M., et al (2017). Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''. British Journal of Cancer, 116(8), 1-1. [More Information]
• Carlino, M., Sandhu, S. (2017). Safety and Efficacy Implications of Discontinuing Combination Ipilimumab and Nivolumab in Advanced Melanoma. Journal of Clinical Oncology, 35(34), 3792-3793. [More Information]
• Long, G., Atkinson, V., Cebon, J., Jameson, M., Fitzharris, B., McNeil, C., Hill, A., Ribas, A., Atkins, M., Thompson, J., Menzies, A., Guminski, A., Kong, B., Lomax, A., Carlino, M., et al (2017). Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. The Lancet Oncology, 18(9), 1202-1210. [More Information]

2016

• Liniker, E., Menzies, A., Kong, B., Cooper, A., Ramanujam, S., Lo, S., Kefford, R., Fogarty, G., Guminski, A., Wang, T., Carlino, M., Hong, A., Long, G. (2016). Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. OncoImmunology, 5(9), 1-7. [More Information]
• Janssen, A., Shaw, T., Nagrial, A., Pene, C., Rabbets, M., Carlino, M., Zachulski, C., Phillips, J., Birnbaum, R., Gandhi, T., Harnett, P. (2016). An Online Learning Module to Increase Self-Efficacy and Involvement in Care for Patients With Advanced Lung Cancer: Research Protocol. Journal of Medical Internet Research, 5(3), 1-8. [More Information]
• Kong, B., Micklethwaite, K., Swaminathan, S., Kefford, R., Carlino, M. (2016). Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Research, 26(2), 202-204. [More Information]
• Hwang, S., Carlos Minano, G., Chou, S., Wakade, D., Carlino, M., Fernandez Penas, P. (2016). Bullous pemphigoid, an autoantibody-mediated disease, is a novel immune-related adverse event in patients treated with anti-programmed cell death 1 antibodies. Melanoma Research, 26(4), 413-416. [More Information]
• Carlino, M., Vanella, V., Girgis, C., Giannarelli, D., Guminski, A., Festino, L., Kefford, R., Menzies, A., Long, G., Ascierto, P. (2016). Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: A case series. British Journal of Cancer, 115(11), 1280-1284. [More Information]
• Hwang, S., Carlos Minano, G., Wakade, D., Byth Wilson, K., Kong, B., Chou, S., Carlino, M., Kefford, R., Fernandez Penas, P. (2016). Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: A single-institution cohort. Journal Of The American Academy Of Dermatology, 74(3), 455-461. [More Information]
• Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Long, G., Carlino, M., et al (2016). Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy. British Journal of Cancer, 114(10), 1084-1089. [More Information]
• Carlino, M., Long, G. (2016). Ipilimumab combined with nivolumab: A standard of care for the treatment of advanced melanoma? Clinical Cancer Research, 22(16), 3992-3998. [More Information]
• Johnson, D., Sullivan, R., Ott, P., Carlino, M., Khushalani, N., Ye, F., Guminski, A., Puzanov, I., Lawrence, D., Buchbinder, E., Menzies, A., Long, G., et al (2016). Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders. JAMA Oncology, 2(2), 234-240. [More Information]
• Atkinson, V., Long, G., Menzies, A., McArthur, G., Carlino, M., Millward, M., Roberts-Thomson, R., Brady, B., Kefford, R., Haydon, A., et al (2016). Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists. Asia-Pacific Journal of Clinical Oncology, 12(Suppl. 7), 5-12. [More Information]
• Lee, J., Kefford, R., Carlino, M. (2016). PD-1 and PD-L1 inhibitors in melanoma treatment: Past success, present application and future challenges. Immunotherapy, 8(6), 733-746. [More Information]
• Kong, B., Menzies, A., Saunders, C., Liniker, E., Ramanujam, S., Guminski, A., Kefford, R., Long, G., Carlino, M. (2016). Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy. Pigment Cell & Melanoma Research, 29(5), 572-577. [More Information]

2015

• Chan, M., Kefford, R., Carlino, M., Clements, A., Manolios, N. (2015). Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma. Journal of Immunotherapy, 38(1), 37-39. [More Information]
• Gray, E., Rizos, H., Reid, A., Boyd, S., Pereira, M., Lo, J., Tembe, V., Freeman, J., Lee, J., Scolyer, R., Long, G., Carlino, M., et al (2015). Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget, 6(39), 42008-42018. [More Information]
• Menzies, A., Wilmott, J., Drummond, M., Lo, S., Lyle, M., Chan, M., Thompson, J., Guminski, A., Carlino, M., Scolyer, R., Kefford, R., Long, G. (2015). Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors. Cancer, 121(21), 3826-3835. [More Information]
• Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J., Cowey, C., Lao, C., Schadendorf, D., Dummer, R., Smylie, M., Carlino, M., Long, G., et al (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. New England Journal of Medicine, 373(1), 23-34. [More Information]
• Carlos Minano, G., Anforth, R., Clements, A., Menzies, A., Carlino, M., Chou, S., Fernandez Penas, P. (2015). Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatology, 151(10), 1103-1109. [More Information]
• Wilmott, J., Colebatch, A., Kakavand, H., Shang, P., Carlino, M., Thompson, J., Long, G., Scolyer, R., Hersey, P. (2015). Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma. Modern Pathology, 28(7), 884-894. [More Information]
• Cooper, A., Carlino, M., Kefford, R. (2015). Immune checkpoint inhibitors in melanoma. Melanoma Management, 2(3), 267-284. [More Information]
• Lam, T., Chan, M., Sweeting, A., De Sousa, S., Clements, A., Carlino, M., Long, G., Tonks, K., Chua, E., Kefford, R., Chipps, D. (2015). Ipilimumab-induced hypophysitis in melanoma patients: An Australian case series. Internal Medicine Journal, 45(10), 1066-1073. [More Information]
• Long, G., Carlino, M. (2015). Is chemotherapy still an option in the treatment of melanoma? Annals of Oncology, 26(11), 2203-2204. [More Information]
• Amaravadi, R., Hamilton, K., Ma, X., Piao, S., Del Portillo, A., Nathanson, K., Carlino, M., Long, G., Puzanov, I., Xu, X., et al (2015). Multiple gastrointestinal polyps in patients treated with BRAF inhibitors. Clinical Cancer Research, 21(23), 5215-5221. [More Information]
• Carlino, M., Kwan, V., Miller, D., Saunders, C., Yip, D., Nagrial, A., Tomlinson, J., Grimmond, S., Scolyer, R., Kefford, R., Long, G., et al (2015). New RAS-Mutant Pancreatic Adenocarcinoma With Combined BRAF and MEK Inhibition for Metastatic Melanoma. Journal of Clinical Oncology, 33(11), e52-E56. [More Information]
• Robert, C., Schachter, J., Long, G., Arance, A., Grob, J., Mortier, L., Daud, A., Carlino, M., McNeil, C., Lotem, M., et al (2015). Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine, 372(26), 2521-2532. [More Information]
• Carlino, M., Fung, C., Shahheydari, H., Todd, J., Boyd, S., Irvine, M., Nagrial, A., Scolyer, R., Kefford, R., Long, G., Rizos, H. (2015). Pre-existing MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients. Clinical Cancer Research, 21(1), 98-105. [More Information]
• Menzies, A., Atkinson, V., Brown, M., Carlino, M., Cebon, J., Guminski, A., Kefford, R., Long, G., McArthur, G., McNeil, C., et al (2015). Sentinel node biopsy for melanoma: The medical oncology perspective. Australian Family Physician, 44(12), 875-876.
• Carlino, M., Long, G., Kefford, R., Rizos, H. (2015). Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. Critical Reviews in Oncology / Hematology (online), 96(3), 385-398. [More Information]

2014

• Rizos, H., Menzies, A., Pupo, G., Carlino, M., Fung, C., Hyman, J., Haydu, L., Mijatov, B., Becker, T., Boyd, S., Howle, J., Saw, R., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2014). BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact. Clinical Cancer Research, 20(7), 1965-1977. [More Information]
• Carlino, M., Haydu, L., Kakavand, H., Menzies, A., Hamilton, A., Yu, B., Ng, C., Cooper, W., Thompson, J., Kefford, R., O'Toole, S., Scolyer, R., Long, G. (2014). Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 111(2), 292-299. [More Information]
• Carlino, M., Todd, J., Gowrishankar, K., Mijatov, B., Pupo, G., Fung, C., Snoyman, S., Hersey, P., Long, G., Kefford, R., Rizos, H. (2014). Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma. Molecular Oncology, 8(3), 544-554. [More Information]
• Long, G., Fung, C., Menzies, A., Pupo, G., Carlino, M., Hyman, J., Shahheydari, H., Tembe, V., Thompson, J., Saw, R., Howle, J., Scolyer, R., Kefford, R., Rizos, H., et al (2014). Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma. Nature Communications, 5, 1-9. [More Information]
• Menzies, A., Haydu, L., Carlino, M., Azer, M., Carr, P., Kefford, R., Long, G. (2014). Inter- and Intra-Patient Heterogeneity of Response and Progression to Targeted Therapy in Metastatic Melanoma. PloS One, 9(1), 1-9. [More Information]
• Carlino, M., Todd, J., Rizos, H. (2014). Resistance to c-Kit inhibitors in melanoma: Insights for future therapies. Oncoscience, 1(6), 423-426. [More Information]

2013

• Carlino, M., Saunders, C., Haydu, L., Menzies, A., Curtis, C., Lebowitz, P., Kefford, R., Long, G. (2013). 18F-labelled fluorodeoxyglucose-positron emission tomography (FDG-PET) heterogeneity of response is prognostic in dabrafenib treated BRAF mutant metastatic melanoma. European Journal of Cancer, 49(2), 395-402. [More Information]
• Gowrishankar, K., Carlino, M., Rizos, H. (2013). Acquired Resistance to Targeted MAPK Inhibition in Melanoma. In Guy Huynh Thien Duc (Eds.), Melanoma - From Early Detection to Treatment, (pp. 197-218). Croatia: InTech Publishers. [More Information]
• Carlino, M., Gowrishankar, K., Saunders, C., Pupo, G., Snoyman, S., Zhang, X., Saw, R., Becker, T., Kefford, R., Long, G., Rizos, H. (2013). Antiproliferative Effects of Continued Mitogen-Activated Protein Kinase Pathway Inhibition Following Acquired Resistance to BRAF and/or MEK Inhibition in Melanoma. Molecular Cancer Therapeutics, 12(7), 1332-1342. [More Information]

2012

• Menzies, A., Haydu, L., Visintin, L., Carlino, M., Howle, J., Thompson, J., Kefford, R., Scolyer, R., Long, G. (2012). Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma. Clinical Cancer Research, 18(12), 3242-3249. [More Information]
• Carlino, M., Fogarty, G., Long, G. (2012). Treatment of Melanoma Brain Metastases: A New Paradigm. The Cancer Journal, 18(2), 208-212. [More Information]